Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will release its earnings data before the market opens on Thursday, November 7th. Analysts expect Aurinia Pharmaceuticals to post earnings of $0.02 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Aurinia Pharmaceuticals Stock Up 0.3 %

NASDAQ AUPH traded up $0.02 during trading on Tuesday, hitting $7.23. The stock had a trading volume of 312,212 shares, compared to its average volume of 1,590,914. Aurinia Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $10.05. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.82 and a current ratio of 5.33. The company’s 50-day moving average price is $7.04 and its two-hundred day moving average price is $6.05. The company has a market capitalization of $1.03 billion, a PE ratio of -21.21 and a beta of 1.45.

Analyst Ratings Changes

Several brokerages recently commented on AUPH. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.